PHAXIAM Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De winst van PHAXIAM Therapeutics zal naar verwachting dalen met 3.5% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 92.4% per jaar. De winst per aandeel zal naar verwachting afnemen met 1.7% per jaar.

Belangrijke informatie

-3.5%

Groei van de winst

-1.7%

Groei van de winst per aandeel

Biotechs winstgroei	8.4%
Inkomstengroei	92.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	10 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

ENXTPA:PHXM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	13	-19	-39	N/A	2
12/31/2025	2	-32	-33	N/A	2
12/31/2024	1	-25	-29	N/A	2
6/30/2024	2	-22	N/A	N/A	N/A
3/31/2024	2	-23	N/A	N/A	N/A
12/31/2023	1	-23	-25	-24	N/A
9/30/2023	6	-12	N/A	N/A	N/A
6/30/2023	6	-11	-23	-23	N/A
3/31/2023	6	6	N/A	N/A	N/A
12/31/2022	7	0	-32	-32	N/A
9/30/2022	2	-18	N/A	N/A	N/A
6/30/2022	3	-27	-45	-45	N/A
3/31/2022	3	-54	N/A	N/A	N/A
12/31/2021	4	-54	-57	-57	N/A
9/30/2021	4	-61	N/A	N/A	N/A
6/30/2021	4	-66	-55	-55	N/A
3/31/2021	4	-68	N/A	N/A	N/A
12/31/2020	4	-73	-53	-52	N/A
9/30/2020	4	-73	N/A	N/A	N/A
6/30/2020	4	-68	-52	-49	N/A
3/31/2020	5	-69	N/A	N/A	N/A
12/31/2019	5	-63	-63	-43	N/A
9/30/2019	6	-52	-69	-38	N/A
6/30/2019	5	-49	-73	-52	N/A
3/31/2019	4	-38	N/A	N/A	N/A
12/31/2018	4	-38	-53	-48	N/A
9/30/2018	3	-42	N/A	N/A	N/A
6/30/2018	4	-38	-33	-31	N/A
3/31/2018	3	-39	N/A	N/A	N/A
12/31/2017	3	-34	N/A	-25	N/A
9/30/2017	4	-27	N/A	N/A	N/A
6/30/2017	4	-26	N/A	-23	N/A
3/31/2017	5	-24	N/A	N/A	N/A
12/31/2016	4	-22	N/A	-18	N/A
9/30/2016	4	-20	N/A	-17	N/A
6/30/2016	4	-19	N/A	-17	N/A
3/31/2016	3	-16	N/A	N/A	N/A
12/31/2015	3	-15	N/A	-15	N/A
9/30/2015	3	-14	N/A	-12	N/A
6/30/2015	2	-12	N/A	-10	N/A
3/31/2015	2	-11	N/A	-9	N/A
12/31/2014	2	-9	N/A	-7	N/A
9/30/2014	2	-8	N/A	-7	N/A
6/30/2014	2	-7	N/A	-6	N/A
3/31/2014	2	-8	N/A	-6	N/A
12/31/2013	2	-8	N/A	-6	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PHXM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PHXM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PHXM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PHXM ( 92.4% per jaar) zal naar verwachting sneller groeien dan de markt French ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van PHXM ( 92.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PHXM naar verwachting over 3 jaar hoog zal zijn

PHAXIAM Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to €5.80

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Recent updates

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Price target decreased to €5.80

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Analysts Expect Breakeven For ERYTECH Pharma S.A. (EPA:ERYP) Before Long

Price target decreased to €14.50

Consensus forecasts updated

Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?

Analysts update estimates

Earnings beat expectations, revenue disappoints

New 90-day low: €6.63

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma's (EPA:ERYP) Stock Price Has Reduced 60% In The Past Five Years

New 90-day high: €8.88

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma (EPA:ERYP) Has Debt But No Earnings; Should You Worry?

New 90-day high: €8.02

New 90-day high: €6.50

Analysts update estimates

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.24

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.95

New 90-day low - €5.51

New 90-day low - €6.06

New 90-day low - €6.74

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven